# TEMODAR® (temozolomide) - Comprehensive FDA Prescribing Information (2015 Update)

**Source**: FDA Complete Prescribing Information from JSON Database  
**Revision Date**: September 2015  
**Initial U.S. Approval**: 1999  
**Extracted**: September 2024

---

## CRITICAL SAFETY UPDATES

### HEPATOTOXICITY WARNING
⚠️ **FATAL AND SEVERE HEPATOTOXICITY REPORTED**

**Monitoring Requirements:**
- **Baseline**: Liver function tests before starting treatment
- **Midway through Cycle 1**: LFTs during first cycle
- **Before each cycle**: LFTs prior to subsequent cycles  
- **Post-treatment**: LFTs 2-4 weeks after last dose

### DRUG INTERACTIONS

#### Valproic Acid Interaction
- **Effect**: Decreases oral clearance of temozolomide
- **Clinical significance**: May increase temozolomide exposure
- **Monitoring**: Enhanced toxicity surveillance required

#### Aplastic Anemia Complications
- **Concomitant medications** complicate assessment:
  - Carbamazepine
  - Phenytoin
  - Sulfamethoxazole/trimethoprim
- **Note**: These drugs also associated with aplastic anemia

---

## DETAILED DOSING PROTOCOLS

### Body Surface Area (BSA) Dose Calculations

| BSA (m²) | 75 mg/m² | 150 mg/m² | 200 mg/m² |
|----------|-----------|-----------|-----------|
| 1.0 | 75 mg | 150 mg | 200 mg |
| 1.1 | 82.5 mg | 165 mg | 220 mg |
| 1.2 | 90 mg | 180 mg | 240 mg |
| 1.3 | 97.5 mg | 195 mg | 260 mg |
| 1.4 | 105 mg | 210 mg | 280 mg |
| 1.5 | 112.5 mg | 225 mg | 300 mg |
| 1.6 | 120 mg | 240 mg | 320 mg |
| 1.7 | 127.5 mg | 255 mg | 340 mg |
| 1.8 | 135 mg | 270 mg | 360 mg |
| 1.9 | 142.5 mg | 285 mg | 380 mg |
| 2.0 | 150 mg | 300 mg | 400 mg |
| 2.1 | 157.5 mg | 315 mg | 420 mg |
| 2.2 | 165 mg | 330 mg | 440 mg |
| 2.3 | 172.5 mg | 345 mg | 460 mg |
| 2.4 | 180 mg | 360 mg | 480 mg |
| 2.5 | 187.5 mg | 375 mg | 500 mg |

### Capsule Combination Guide (Selected Doses)

| Daily Dose | 250mg | 180mg | 140mg | 100mg | 20mg | 5mg |
|------------|--------|-------|-------|-------|------|-----|
| 75 mg | 0 | 0 | 0 | 0 | 3 | 3 |
| 150 mg | 0 | 0 | 1 | 0 | 0 | 2 |
| 200 mg | 0 | 1 | 0 | 0 | 1 | 0 |
| 255 mg | 1 | 0 | 0 | 0 | 0 | 1 |
| 300 mg | 0 | 0 | 0 | 3 | 0 | 0 |
| 420 mg | 0 | 0 | 3 | 0 | 0 | 0 |
| 500 mg | 2 | 0 | 0 | 0 | 0 | 0 |

---

## ENHANCED MONITORING PROTOCOLS

### Concomitant Phase Laboratory Monitoring
- **Frequency**: Weekly complete blood count
- **Duration**: Throughout 42-day concomitant period
- **Continuation criteria**: All must be met:
  - ANC ≥1.5 × 10⁹/L
  - Platelets ≥100 × 10⁹/L  
  - Non-hematologic toxicity ≤Grade 1 (except alopecia, nausea, vomiting)

### Maintenance Phase Monitoring Schedule
- **Day 1**: CBC before each cycle
- **Day 22**: CBC (21 days after first dose) ±48 hours
- **Weekly**: Until ANC >1.5 × 10⁹/L and platelets >100 × 10⁹/L
- **Next cycle**: Cannot start until counts recovered

### Dose Modification Flowchart

**Starting Dose: 150 or 200 mg/m²/day × 5 days**

↓

**Day 22 Monitoring**: ANC and platelet counts

↓

**Day 29 Assessment**: Based on lowest counts (Day 22 or 29)

**Three Pathways:**

1. **ANC <1000/μL OR Platelets <50,000/μL**
   - Postpone until recovery (ANC >1500, PLT >100,000)
   - Reduce dose by 50 mg/m² for next cycle

2. **ANC 1000-1500/μL OR Platelets 50,000-100,000/μL**
   - Postpone until recovery
   - Maintain current dose

3. **ANC >1500/μL AND Platelets >100,000/μL**
   - Increase to or maintain 200 mg/m² × 5 days

---

## ADMINISTRATION DETAILS

### Oral Capsule Administration
- **Timing**: On empty stomach to reduce nausea
- **Method**: Swallow whole with water - DO NOT open or chew
- **Handling**: Avoid inhalation/skin contact if capsule damaged
- **Timing option**: Bedtime administration may reduce nausea

### Intravenous Administration
- **Reconstitution**: 41 mL Sterile Water = 2.5 mg/mL solution
- **Infusion time**: **EXACTLY 90 minutes** (bioequivalence established only at 90 min)
- **Compatibility**: 0.9% Sodium Chloride injection ONLY
- **Stability**: Use within 14 hours including infusion time
- **Volume**: Up to 40 mL per vial, transfer to 250 mL infusion bag

---

## PNEUMOCYSTIS PNEUMONIA (PCP) PROPHYLAXIS

### Mandatory Requirements
- **All patients** receiving concomitant TEMODAR + radiotherapy
- **Duration**: During 42-day concomitant regimen
- **Continuation**: Until lymphocytopenia recovery to ≤Grade 1
- **High-risk patients**: Those receiving steroids require close monitoring

---

## CONTRAINDICATIONS AND HYPERSENSITIVITY

### Absolute Contraindications
- Hypersensitivity to any TEMODAR component
- **DACARBAZINE (DTIC) hypersensitivity** - both metabolized to MTIC

### Hypersensitivity Reactions Include:
- Urticaria
- Allergic reactions including anaphylaxis
- Toxic epidermal necrolysis
- Stevens-Johnson syndrome

---

## MYELOSUPPRESSION MANAGEMENT

### High-Risk Populations
- **Geriatric patients**: Higher myelosuppression risk
- **Women**: Higher myelosuppression risk than men

### Aplastic Anemia Warning
- May result in **fatal aplastic anemia**
- Risk increased with prolonged pancytopenia
- Monitor for secondary malignancies including:
  - Myelodysplastic syndrome
  - Myeloid leukemia

---

## SPECIAL POPULATIONS

### Pregnancy (Category D)
- **Fetal harm**: Documented at 0.38-0.75× max human dose
- **Animal studies**: Fetal malformations in rats and rabbits
- **Contraception**: Required during treatment

### Renal/Hepatic Impairment
- **Severe renal impairment**: Use with caution
- **Severe hepatic impairment**: Use with caution
- **No specific dose adjustments**: Established guidelines not available

### Pediatric Use
- **<3 years**: No established use
- **≥3 years**: Limited safety/efficacy data

---

## OVERDOSAGE
- **No specific antidote** available
- **Supportive care**: Monitor blood counts
- **Expected toxicity**: Severe myelosuppression

---

## STORAGE AND HANDLING

### Capsules
- **Temperature**: Controlled room temperature
- **Container**: Keep tightly closed
- **Moisture**: Protect from moisture

### Injection
- **Before reconstitution**: Room temperature
- **After reconstitution**: Use within 14 hours
- **Handling**: Use appropriate cytotoxic precautions

---

## PATIENT COUNSELING POINTS

1. **Take on empty stomach** (except if nausea severe)
2. **Report fever, unusual bleeding/bruising** immediately
3. **Avoid pregnancy** during treatment and 6 months after
4. **Complete blood count monitoring** is essential
5. **Liver function monitoring** required throughout treatment
6. **Drug interactions**: Report all medications including OTC
7. **Infection risk**: Monitor for signs of infection, especially PCP

---

*This comprehensive prescribing information incorporates the complete 2015 FDA labeling updates including critical hepatotoxicity warnings, detailed dosing tables, and enhanced safety monitoring protocols essential for clinical practice.*